Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma

Huang, Pinzhu; Liu, Chunhong; Li, Binkui; Zheng, Yun; Zou, Ruhai; Huang, Jun; Hu, Zemin; Yuan, Yufeng

doi:10.3892/mco.2015.705

Cited by 7 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the included studies, 18 studies[ 15 , 17 , 22 , 24 , 25 , 27 - 32 , 34 - 40 ] reported 30-d mortality rates whereas only two studies[ 36 , 39 ] reported 90-d mortality rates (Figure 4 ). While resection of non-giant HCC had lower odds of death within the first 30 d after surgery, the difference was not statistically significant (OR 0.73, 95%CI: 0.50-1.08, P = 0.116).…”

Section: Resultsmentioning

confidence: 99%

“…Among the included studies, 20 studies[ 14 - 16 , 21 - 25 , 27 - 34 , 36 - 38 , 40 ] reported on vascular invasion, 13 studies[ 15 , 16 , 21 , 22 , 24 , 27 - 29 , 31 , 32 , 37 , 39 , 40 ] on cirrhosis, 16 studies[ 15 , 16 , 22 , 23 , 25 , 27 , 28 , 30 - 37 , 39 , 40 ] on Child Pugh’s score and 9 studies[ 21 , 22 , 24 , 27 , 29 , 32 , 34 , 37 , 40 ] on tumor number (Table 3 ). While non-giant HCC was found to have significantly lower odds of vascular invasion (OR 0.367, 95%CI: 0.236-0.572, P < 0.0001) and multinodular tumors (OR 0.592, 95%CI: 0.376-0.939, P < 0.0259), it was found to have significantly higher odds of cirrhosis (OR 1.955, 95%CI: 1.317-2.903, P = 0.0009).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis

Lee¹,

Wu²,

Yew³

et al. 2023

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND Research on long-term survival after resection of giant (≥ 10 cm) and non-giant hepatocellular carcinoma (HCC) (< 10 cm) has produced conflicting results. AIM This study aimed to investigate whether oncological outcomes and safety profiles of resection differ between giant and non-giant HCC. METHODS PubMed, MEDLINE, EMBASE, and Cochrane databases were searched. Studies designed to investigate the outcomes of giant vs non-giant HCC were included. The primary endpoints were overall survival (OS) and disease-free survival (DFS). The secondary endpoints were postoperative complications and mortality rates. All studies were assessed for bias using the Newcastle–Ottawa Scale. RESULTS 24 retrospective cohort studies involving 23747 patients (giant = 3326; non-giant = 20421) who underwent HCC resection were included. OS was reported in 24 studies, DFS in 17 studies, 30-d mortality rate in 18 studies, postoperative complications in 15 studies, and post-hepatectomy liver failure (PHLF) in six studies. The HR was significantly lower for non-giant HCC in both OS (HR 0.53, 95%CI: 0.50-0.55, P < 0.001) and DFS (HR 0.62, 95%CI: 0.58-0.84, P < 0.001). No significant difference was found for 30-d mortality rate (OR 0.73, 95%CI: 0.50-1.08, P = 0.116), postoperative complications (OR 0.81, 95%CI: 0.62-1.06, P = 0.140), and PHLF (OR 0.81, 95%CI: 0.62-1.06, P = 0.140). CONCLUSION Resection of giant HCC is associated with poorer long-term outcomes. The safety profile of resection was similar in both groups; however, this may have been confounded by reporting bias. HCC staging systems should account for the size differences.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis

Lee¹,

Wu²,

Yew³

et al. 2023

World J Gastrointest Surg

View full text Add to dashboard Cite

show abstract

“… 26 Anemia is a common complication in HCC patients, and previous evidence has indicated its correlated with poor clinical prognosis in HCC. 27 Elevated hemoglobin levels may be a compensatory response to the presence of massive tumors that have outgrown their vascular supply, leading to local ischemia and hypoxia. 28 The association between high hemoglobin levels and poor survival observed in our study suggests that this phenomenon may serve as a prognostic indicator.…”

Section: Discussionmentioning

confidence: 99%

Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis

Lim,

Kim,

Rhu

et al. 2024

JLC

View full text Add to dashboard Cite

Background/Aim: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the clinicopathological characteristics and risk factors for HCC recurrence and mortality following liver resection (LR) in patients with Vp3 or Vp4 HCC.Methods: The study included 64 patients who underwent LR for HCC with Vp3 or Vp4 portal vein tumor thrombosis (PVTT).Results: Fifty-eight patients (90.6%) had Vp3 PVTT, whereas the remaining six patients exhibited Vp4 PVTT. The median tumor size measured 8 cm, with approximately 36% of patients presented with multiple tumors. Fifty-four patients (84.4%) underwent open LR, whereas 10 patients underwent laparoscopic LR. In the Vp4 cases, combined LR and tumor thrombectomy were performed. The 3-year cumulative disease-free survival rate was 42.8% for the Vp3 group and 22.2% for the Vp4 group. The overall survival (OS) rate at 3 years was 47.9% for the Vp3 group and 60.0% for the Vp4 group. Intrahepatic metastasis has been identified as an important contributor to HCC recurrence. High hemoglobin levels are associated with high mortality.Conclusion: LR is a safe and effective treatment modality for selected patients with Vp3 or Vp4 HCC PVTT. This suggests that LR is a viable option for these patients, with favorable outcomes in terms of OS.

show abstract

“…MCH is a measurement of the average HGB content of each RBC ( 11 ). One small-scale retrospective study revealed that a low MCH level was associated with worse survival in hepatectomized patients with hepatocellular carcinoma ( 11 ), and MCH was shown to be a marker of iron metabolism. As demonstrated in previous reports, abnormalities in iron metabolism might be crucial in cancer progression ( 32 , 33 ).…”

Section: Discussionmentioning

confidence: 99%

“…MCV is a measurement of RBC size ( 9 ), which could reflect folate deficiency ( 10 ). MCH refers to a calculation of the average HGB content of each RBC, another factor correlated with anemia that represents the iron metabolism ( 11 ). MCHC is calculated by dividing the HGB by the HCT and can reflect average HGB concentration ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers

Cui¹,

Liang²,

Sun³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. This study was designed to investigate the prognostic values of red blood cell (RBC)-associated indicators, including RBC, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and RBC distribution width (RDW) in resectable GC patients. Methods In this retrospective study, a total of 104 pathologically confirmed GC patients were recruited. These cases were divided into two groups according to the median values of pretreatment RBC, HGB, HCT, MCV, MCH, MCHC, or RDW. To evaluate the changes in RBC-associated indicators values after treatment, we introduced the concept of post-/pre-treatment ratios (≤1 suggested RBC, HGB, HCT, MCV, MCH, MCHC, or RDW values were not increased after therapy, while >1 represented those in increased levels). Results The lower pretreatment MCHC levels were correlated with worse overall survival (OS), while pretreatment levels of RBC, HGB, HCT, MCV, MCH, or RDW were not. The whole course of treatment (surgery plus adjuvant chemotherapy) significantly decreased the values of MCHC, and increased the values of MCV and RDW, whereas it had no obvious effects on the values of RBC, HGB, HCT, or MCH. Patients with post-/pre-treatment MCV ratio >1 had an increased survival ratio. Meanwhile, post-/pre-treatment RBC, HGB, HCT, MCH, MCHC, or RDW ratios were not correlated with outcomes. Multivariate Cox regression analysis revealed that the American Joint Committee on Cancer (AJCC) stage (III), and lower pretreatment MCHC levels were independent risk factors affecting OS. The receiver operating characteristic (ROC) curve analysis showed that an MCHC value of 341.98 g/L was the optimal cutoff value for prognosis, with a sensitivity of 58.3% and a specificity of 75.0%. Conclusions Pretreatment MCHC levels could become a potential prognostic factor for resectable GC.

show abstract

Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma

Cited by 7 publications

References 36 publications

Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis

Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis

Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis

The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers

Contact Info

Product

Resources

About